Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

Biochemical Pharmacology

Volumn 55, Issue 10, 1998, Pages 1567-1572

  Fu, Lei ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Hepatitis B virus (HBV); L( )SddC (3TC); Mutations outside YMDD motif; Site directed mutagenesis; YMDD motif

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG;

AMINO ACID SUBSTITUTION; ARTICLE; DNA REPLICATION; DRUG ACTIVITY; DRUG SENSITIVITY; GENE MUTATION; GENETIC TRANSFECTION; HEPATITIS B VIRUS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; STRUCTURAL GENE; VIRUS GENOME; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; BASE SEQUENCE; DNA PRIMERS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MICROBIAL; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTAGENESIS, SITE-DIRECTED; MUTATION; TUMOR CELLS, CULTURED;

EID: 0032525030     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00050-1     Document Type: Article

References (22)

1. Tiollais P, Buendia MA. Hepatitis B virus. Sci Am. 264:1991;116-123.
2. Cromlish JA. Hepatitis B virus-induced hepatocellular carcinoma Possible roles for HBx . Trends Microbiol. 4:1996;270-274.
3. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA. 88:1991;8495-8499.
4. Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver. 17:1997;103-106.
5. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 333:1995;1657-1661.
6. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
7. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
8. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22.
9. Honkoop P, Niesters HGM, de Man RAM, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol. 26:1997;1393-1395.
10. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8:1989;3867-3874.
11. Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron JM. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 37:1993;2231-2234.
12. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol. 47:1994;155-169.
13. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA. 90:1993;5653-5656.
14. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J, Boucher CAB. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 171:1995;1411-1419.
15. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, Gu Z, Song Q, Manne J, Islam S, Castriota G, Prasad VR. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 271:1996;1282-1285.
16. Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-β-L-2′,3′-dideoxy-3′-thiacytidine] in vitro. Antimicrob Agents Chemother. 40:1996;1957-1960.
17. Fu L, Wu X, Kong YY, Wang Y. Regulation of hepatitis B virus gene expression by its enhancers. Acta Biochim Biophys Sinica. 28:1996;590-599.
18. Fu L, Wu X, Kong YY, Wang Y. Regulation of HBV gene expression by core promoter and its upstream sequences. Chin J Virol. 13:1997;215-223.
19. Sambrook J, Fritsch EF and Maniatis T, Molecular Cloning: A Laboratory Manual, 2nd Edn, pp. 16.32-16.36. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
20. Cullen BR, Malim MH. Secreted placental alkaline phosphatase as a eukaryotic reporter gene. Methods Enzymol. 216:1992;362-368.
21. King RW, Ladner SK. Reduced replication efficiency of 3TC-resistant human hepatitis B virus. Antiviral Res. 34:1997;A52.
22. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, Locarnini S. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol. 26:1997;1148-1153.